Cancer Genetics $48m IPO marches on, in spite of cancellation rumours
This article was originally published in Clinica
Executive Summary
Rumours of the demise of Cancer Genetics' $48m planned initial public offering (IPO) have been exaggerated, according to sources close to the matter. The Rutherford, New Jersey firm first revealed its IPO plans in December, and disclosed more details earlier this month, when it said it would be offering four million shares priced at $11-13 (www.clinica.co.uk, 9 May 2012).